Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xenova (XNVA) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (87)	9/29/2004 8:19:57 AM
From: tom pope	Respond to of 173

This is what Garren had to say about NABI this a.m.: Nabi (NABI) was another big mover today. This is one of the biggest positions in the Model Portfolio. The move was based on positive Phase II data on NicVAX, a vaccine to help patients stop smoking. At the highest NicVAX dose level 33% of patients quite smoking versus only 9% in the placebo group. This could be a very nice product for a condition that is the highest risk factor for lung cancer. It certainly looks like it works and has a very benign side effect profile. Hard core smokers are difficult to get into treatment programs but I think there is a very big market for this type of vaccine. However, I still see StaphVAX as being the big driver. I am holding my Nabi and would recommend accumulating at this price level He doesn't own XNVA